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Abstract
Background: Dysfunction of the serotonergic (5-HTergic) system has been implicated in the cognitive and behavioural
symptoms of Alzheimer’s disease (AD). Accumulation of toxic amyloid-β (Aβ) species is a hallmark of AD and an
instigator of pathology. Serotonin (5-HT) augmentation therapy by treatment with selective serotonin reuptake
inhibitors (SSRIs) in patients with AD has had mixed success in improving cognitive function, whereas SSRI
administration to mice with AD-like disease has been shown to reduce Aβ pathology. The objective of this study
was to investigate whether an increase in extracellular levels of 5-HT induced by chronic SSRI treatment reduces Aβ
pathology and whether 5-HTergic deafferentation of the cerebral cortex could worsen Aβ pathology in the
APPswe/PS1ΔE9 (APP/PS1) mouse model of AD.
Methods: We administered a therapeutic dose of the SSRI escitalopram (5 mg/kg/day) in the drinking water of
3-month-old APP/PS1 mice to increase levels of 5-HT, and we performed intracerebroventricular injections of the
neurotoxin 5,7-dihydroxytryptamine (DHT) to remove 5-HTergic afferents. We validated the effectiveness of these
interventions by serotonin transporter autoradiography (neocortex 79.7 ± 7.6%) and by high-performance liquid
chromatography for 5-HT (neocortex 64% reduction). After 6 months of escitalopram treatment or housing after
DHT-induced lesion, we evaluated brain tissue by mesoscale multiplex analysis and sections by IHC analysis.
Results: Amyloid-β-containing plaques had formed in the neocortex and hippocampus of 9-month-old APP/PS1 mice
after 6 months of escitalopram treatment and 5-HTergic deafferentation. Unexpectedly, levels of insoluble Aβ42 were
unaffected in the neocortex and hippocampus after both types of interventions. Levels of insoluble Aβ40 increased in
the neocortex of SSRI-treated mice compared with those treated with vehicle control, but they were unaffected in the
hippocampus. 5-HTergic deafferentation was without effect on the levels of insoluble/soluble Aβ42 and Aβ40 in both
the neocortex and hippocampus. However, levels of soluble amyloid precursor protein α were reduced in the
neocortex after 5-HTergic deafferentation.
Conclusions: Because this study shows that modulation of the 5-HTergic system has either no effect or increases
levels of insoluble/soluble Aβ42 and Aβ40 in the cerebral cortex of APP/PS1 mice, our observations do not support
5-HT augmentation therapy as a preventive strategy for reducing Aβ pathology.
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fluid (CSF), Biomarker
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Background
Alzheimer’s disease (AD) is a devastating neurodegen-
erative disorder characterised by amyloid and tau path-
ology, as well as a progressive decay of brain circuitry,
leading to cognitive impairment especially affecting
memory [1]. In addition to the cholinergic degenera-
tive damage in AD [2], deterioration of the serotoner-
gic (5-HTergic) system has also attracted attention for
its involvement in AD presentation because the 5-
HTergic system is involved in the regulation of mood [3]
and in memory function [4]. Changes of the 5-HTergic
system in AD include loss of raphe neurons [5, 6], reduced
activity of tryptophan hydroxylase [7] and a reduction in
cortical levels of serotonin (5-HT) [8, 9]. It has been sug-
gested that AD pathology may even originate in the brain-
stem, which contains the 5-HTergic neurons clustered in
the raphe nuclei [10, 11].
The effect of 5-HT augmentation therapy on cognitive
function in patients with AD has been examined in
placebo-controlled studies with use of selective sero-
tonin reuptake inhibitors (SSRIs) [12–15], but these
studies have had limited success [16]. Retrospective co-
hort studies, however, reported that SSRI treatment re-
duces cognitive decline and rate of dementia, although
not to the level of the general population [17, 18]. Con-
versely, reducing levels of 5-HT by acute tryptophan de-
pletion worsens cognitive function in patients with AD
[19].
As observed in patients with AD [20], ageing
APPSWE/PS1ΔE9 (APP/PS1)-transgenic mice [21] pro-
gressively accumulate amyloid-β (Aβ) in their cortex
[22] and have reduced density of 5-HTergic fibres and
reduced levels of 5-HT [23]. Peroral treatment with 8
mg/kg/day citalopram during a period of 4 months has
been reported to reduce Aβ pathology in the neocortex
and hippocampus of 7-month-old APP/PS1 mice [24].
Intraperitoneal injection of 5 mg/kg/day paroxetine for
5 months has been shown to retard accumulation of
Aβ40 and tau pathology in the hippocampus of 10-
month-old triple-transgenic (3 × Tg) mice [25]. A study
of amyloid pathology in the hippocampal CA1 region
in 3 × Tg mice fed a high-tryptophan diet for 1 month
showed reduction of pathology, which was inversely
related to the density of 5-HTergic fibres [26]. Conversely,
the opposite strategy of inflicting neurotoxin-induced 5-
HTergic deafferentation of the forebrain was shown to
reduce levels of tau phosphorylation in the neocortex, but
not amyloid pathology, in APP/PS1 mice [27].
Given the mixed results of clinical studies and the lim-
ited availability of in vivo studies addressing the effect of
5-HT on Aβ pathology in preclinical models of familial
AD, we designed this study to investigate the long-term
effect of 5-HT augmentation therapy on cerebrospinal
fluid (CSF) and brain levels of Aβ in APP/PS1 mice. To
this end, one of the most widely used and most sero-
tonin-selective SSRIs, escitalopram, was administered to
3-month-old APP/PS1 mice for a period of 6 months at a
therapeutically relevant dosage of 5 mg/kg/day. In
addition, neurotoxin-induced degeneration of the 5-
HTergic system was used to study the effect of chronic 5-
HT reduction on brain levels of Aβ in the APP/PS1
mouse.
After 6 months of treatment with escitalopram, levels
of Aβ40 increased in the neocortex of APP/PS1 mice,
whereas CSF levels of Aβ were unaffected. 5-HT deaffer-
entation had no effect on any Aβ species, but it did
affect levels of soluble amyloid precursor protein α
(sAPPα). These results demonstrate that chronic modu-
lation of the 5-HTergic system in prodromal and early
AD-like pathology in mice may be inefficient and even
contraindicated.
Methods
Animals
APP/PS1-Tg mice [21] on a C57BL/6 background were
bred and housed in the animal facility at the University
of Southern Denmark until they reached 9 months of
age. At the age of 3 months, APP/PS1 mice were allo-
cated into groups that were either treated with escitalo-
pram (Cipralex®; Lundbeck A/S, Copenhagen, Denmark)
for 6 months or surgically lesioned with 5,7-dihydroxy-
tryptamine (DHT) and housed for 6 months. Addition-
ally, 9-month-old wild-type littermate mice were
included along with 6-month-old APP/PS1 mice to
evaluate the specificity/sensitivity of the Aβ mesoscale
analysis. Mice were kept in a humidity-controlled
(45–65%) and temperature-controlled (21 ± 1 °C) en-
vironment under a 12:12-h light-dark cycle (lights on
at 7 a.m.) with food and water available ad libitum.
All experiments were carried out in agreement with
the Danish Animal Experiments Inspectorate, Ministry
of Environment and Food (2011/562-67 and 2011/
561-1950).
Treatment with escitalopram
Groups of 3-month-old APP/PS1 mice received 5 mg/
kg/day escitalopram (Cipralex® 20 mg/ml oral drops;
Lundbeck A/S) diluted in normal drinking water to a
final concentration of 0.025 mg/ml in their drinking bot-
tles (n = 10). To avoid potential modifying effects of light
on drug composition, drinking bottles were composed of
a black plastic polymer. Vehicle-treated mice received
normal drinking water (n = 10). The dosage of escitalo-
pram was calculated to result in around 80% occupancy
of the serotonin transporter (SERT), which is considered
therapeutic in humans [28]. Mice were treated for a
period of 6 months, during which their daily water in-
take and intake of escitalopram and body weight were
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calculated on the basis of weekly surveillance. The experi-
ment was terminated when mice reached 9 months of age.
SERT occupancy
Groups of vehicle (n = 3) and 1-month-old escitalopram-
treated mice (n = 3) were killed by cervical dislocation and
investigated by autoradiography. The brains were
immediately removed and frozen in isopentane on dry ice
(−20 °C). Cryostat sections were cut 20 μm thick in the
coronal plane using a cryostat (Leica Biosystems, Buffalo
Grove, IL, USA) and stored at −80 °C for a period of 1
week. Sections were thawed to room temperature (RT),
directly incubated for 5 minutes with 1 nM 3-amino-
4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile
([3H]DASB; specific activity 80 Ci/mmol), and then
dissolved in 50 mM Tris-HCl buffer containing 150
mM NaCl and 5 mM KCl (pH 7.4). Adjacent
sections were incubated under identical conditions in
the presence of 10 μM paroxetine to calculate non-
specific binding. Sections were next washed in ice-
cold 50 mM Tris buffer (twice for 30 seconds each
time), dipped in distilled water, dried under a cold
stream of air for 2 h and desiccated overnight (O/N)
in a box containing silica gel. The sections were
placed on Kodak BioMax MR autoradiography film
(Carestream Health, Skovlunde, Denmark), which
was developed and analysed after 25 days.
Stereotactic 5-HTergic lesion induced by DHT
The 5-HTergic lesion was induced by intracerebroven-
tricular injection of DHT (5,7-dihydroxytryptamine
creatinine sulphate salt, catalogue number 37970;
Sigma-Aldrich, Brøndby, Denmark). Three-month-old
APP/PS1 mice were randomly distributed into groups
of sham- and DHT-lesioned mice (n = 10–13/group).
Before surgery, Tg mice were administered 25 mg/kg
desipramine hydrochloride (catalogue number D3900;
Sigma-Aldrich) diluted in sterile PBS i.p. to prevent
DHT-induced loss of noradrenergic neurons, then they
were anaesthetised by an i.p. injection of a mixture of
fentanyl citrate 0.315 mg/ml and fluanisone 10 mg/ml
(Hypnorm®; VetaPharma, Leeds, UK) and diazepam 5
mg/ml (Stesolid®; Actavis/Accord Healthcare, Little
Island, Ireland) diluted in sterile water. When deeply
anaesthetised, mice were placed in a stereotactic frame
with an attached microinjection unit (David Kopf
Instruments, Tujunga, CA, USA) and injected with 4
μl of a DHT solution (500 mg DHT/ml physiological
saline with 0.1% ascorbic acid, catalogue number
A4544; Sigma-Aldrich,). Sham-operated mice exclu-
sively received the saline composition. DHT and saline
were administered at rates of 1 μl/minute into the left
lateral ventricle using a 10-μl syringe (model 801 RN;
Hamilton, Reno, NV, USA) with the following
coordinates: 1 mm lateral to sagittal suture, 0.5 mm
posterior to bregma and 3.0 mm below the dura mater.
To avoid spillover, syringes were kept in position for 2
minutes after each injection. After surgery, mice
received saline and buprenorphine hydrochloride
(Temgesic® 1 μg/20 g diluted in saline; Reckitt
Benckiser Healthcare, Hull, UK). Mice were placed in
cages located in heated cabinets (28 °C) for 24 h, after
which they were transferred to the animal room and
kept until the age of 9 months.
Harvesting of tissue and cerebrospinal fluid
Mice were anaesthetised with a sublethal dose of
pentobarbital (Nembutal 0.15 ml/30 g body weight i.p.;
Lundbeck) and positioned for CSF removal under a
dissection microscope. The skin of the neck was surgi-
cally removed, and the dura covering the cisterna
magna was exposed. With a thin, pointy glass capillary
tube, the dura was punctured, and 1–5 μl of CSF was
extracted from the cisterna magna and placed on dry
ice before being stored at −80 °C [29]. Next, the brain
was removed, and the right hemisphere was isolated
for IHC. The neocortex and hippocampus were
isolated from the left hemisphere and kept at −80 °C.
Determination of 5-HT and 5-hydroxyindoleacetic acid
Levels of 5-HT were determined using high-
performance liquid chromatography (HPLC) with
electrochemical detection essentially as previously
described [30]. Briefly, the neocortex and hippocampus
were transferred to ice-cold transmitter buffer (150 mM
H3PO4 and 150 μM pentetic acid) and sonicated in three
intervals of 10 seconds each with an amplitude set to
15% (tissue dilution 1:20 wt/vol). The homogenate was
centrifuged at 36,000 × g for 20 minutes at 4 °C, then 40
μl of supernatant was injected into an Agilent 1100
HPLC system (Agilent Technologies, Santa Clara, CA,
USA) consisting of an EC 150/4.6 NUCLEODUR 100 3-
μm C18 gravity reversed-phase column (Machery-Nagel,
Düren, Germany). The electrochemical detector
(Machery-Nagel) was adjusted to +0.75 V against an Ag/
AgCl reference electrode, and the mobile phase
consisted of 16% methanol and 84% phosphate buffer
(0.1 M NaH2PO4, 0.65 mM octanesulfonic acid, 0.5 mM
triethylamine and 0.1 mM ethylenediaminetetraacetic
acid) adjusted to pH 3.35 with H3PO4. Detection limits
for 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) were
20 pg/mg tissue wet weight.
Tissue processing and IHC
Isolated hemispheres were fixed in 4% paraformalde-
hyde (PFA) in Sørensen’s Buffer (SB) for 24 h followed
by 1% PFA in SB for an additional 24 h, after which
they were dehydrated in graded ethanol and xylene and
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embedded in paraffin using an HMP 110 tissue processer
(MICROM International, Dreieich, Germany). Paraffin-
embedded hemispheres were casted into multiblocks and
cut into 20-μm-thick sections using a Shandon Finesse
ME microtome (Thermo Fisher Scientific, Runcorn, UK).
Sections were placed on a water-filled paraffin stretch bath
(TFB 35; Medite, Burgdorf, Germany) at a temperature of
45 °C, mounted on microscope slides and dried O/N.
Next, sections were incubated for 2 h at 60 °C and stored
at 4 °C until use.
Tissue sections were deparaffinised in xylene and
rehydrated in graded ethanol before being rinsed in
deionised H2O. Prior to immunostaining for Aβ, sec-
tions were de-masked in 70% formic acid for 30 mi-
nutes, followed by rinsing in Tris-buffered saline (TBS)
with 1% Triton X-100 (TBS-T) and incubation in TBS
with 10% FBS for 30 minutes to block unspecific bind-
ing. Biotinylated monoclonal mouse anti-human Aβ
antibody (catalogue number BioLegend, San Diego,
CA, USA) diluted 1:500 in TBS with 10% FBS was then
added O/N at 4 °C. Sections were washed in TBS-T
and immersed in TBS/MeOH/H2O2 (8:1:1) for 10 mi-
nutes, and after an additional rinse in TBS-T, they were
incubated with horseradish peroxidase-streptavidin
(catalogue number RPN1231; GE Healthcare Life
Sciences, Brondby, Denmark) diluted 1:200 in TBS
with 10% FBS at RT for 3 h. Sections were developed
by immersion for 5 minutes in TBS with 3,3′-diamino-
benzidine (0.5 mg/ml) and H2O2 (0.033%) added. After
a final TBS rinse, sections were dehydrated in a series
of ethanol followed by xylene and then coverslipped
with PERTEX (HistoLab Products, Askim, Sweden).
Meso Scale Discovery multiplex analysis
To determine the content of Aβ40 and Aβ42 in the neo-
cortex and hippocampus of escitalopram-treated and
DHT-lesioned APP/PS1 mice, samples were sonicated in
ice-cold PBS containing protease and PhosSTOP phos-
phatase inhibitor cocktail (Roche Diagnostics, Mannheim,
Germany). The homogenates were spun at 9000 × g for 20
minutes at 4 °C. Supernatants (PBS fraction) were stored
at −80 °C, and pellets were resuspended in an 8× volume
of 5 M guanidine and 50 mM Tris-HCl buffer. Guanidine
and PBS fractions were diluted 2× for analysis employing
the V-PLEX panels for Aβ40 and Aβ42 (Aβ peptide panel
1; Meso Scale Discovery, Rockville, MD, USA) and the
sAPPα and sw sAPPβ kits (Meso Scale Discovery) in ac-
cordance with the manufacturer’s instructions. Plates were
processed in a SECTOR Imager 6000 instrument (Meso
Scale Discovery), and data were analysed using Discovery
Workbench software (Meso Scale Discovery). Values are
presented as picograms of Aβ per milligram of total
protein.
Statistics
Data were analysed with Prism version 6 software
(GraphPad Software, La Jolla, CA, USA) and are pre-
sented as mean ± SEM of 10 animals/group for the SSRI
study and 10–13 animals/group for the DHT study. Data
from the escitalopram-treated and DHT-lesioned groups
were analysed by unpaired, two-tailed Mann-Whitney U
test. Statistically significant differences are indicated as
*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
Results
Dosing confirmation studies
Given that escitalopram is approximately twice as po-
tent as citalopram [31] and that treatment of APP/
PS1 mice with 8 mg/kg/day citalopram per os was
previously reported to reduce Aβ load in APP/PS1
mice [24], we aimed to treat animals with escitalo-
pram at a dose of 5 mg/kg/day in the drinking water.
To achieve this, the daily water intake of adult APP/
PS1 mice was monitored over a period of 4 weeks (n = 5;
data not shown). Thereafter, the occupancy of SERT fol-
lowing 4 weeks of escitalopram treatment at a nominal
dosage of 5 mg/kg/day was determined to confirm dosing
effectiveness (n = 3) (Fig. 1a, b). The dosage of escitalo-
pram achieved in this study was 3.8 ± 0.2 mg/kg/day
(Additional file 1: Figure S1a–c). Autoradiography
using the SERT-selective radioligand [3H]DASB
showed occupancy levels of 79.7 ± 7.6% in the neocor-
tex and 66.9 ± 2.8% in the hippocampus at this dose
of escitalopram (Fig. 1a, b). On the basis of these
data, we increased the SSRI concentration in the
drinking water to achieve a therapeutically relevant
intake of 5 mg/kg/day.
Daily SSRI intake and effects on body weight
Three-month-old APP/PS1 mice were treated with 5
mg/kg/day escitalopram per os for a period of 6 months,
whereas vehicle control-treated mice received normal
drinking water (n = 10/group). Weight development
(Fig. 1c), daily water intake (Fig. 1d) and the dosage of
escitalopram were monitored throughout the entire ex-
perimental period (Fig. 1e). During the experiment, mice
weighing 27.7 ± 1.6 g (Fig. 1c) drank, on average, 5.20
ml/day/mouse (Fig. 1d), which corresponded to an
intake of escitalopram of 4.79 ± 0.27 mg/kg/day (Fig. 1e).
At the end of the experiment, the body weight of 9-
month-old APP/PS1 mice receiving escitalopram was
comparable to that of vehicle-treated mice (escitalopram
30.5 ± 1.3 g, vehicle 31.4 ± 1.0 g) (Fig. 1c).
Escitalopram treatment invokes subtle changes of
insoluble amyloid-β levels
CSF was drawn immediately prior to the procurement of
the neocortex and hippocampus, and the levels of Aβ40
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and Aβ42 in the CSF were quantified by multiplex ana-
lysis. The levels of Aβ40 and Aβ42 were not different be-
tween escitalopram-treated and vehicle-treated APP/PS1
mice (Fig. 2a). There was an almost significant reduction
in the CSF ratio of Aβ42/Aβ40 in escitalopram-treated
mice compared with vehicle-treated mice (escitalopram
0.20 ± 0.02, vehicle 0.23 ± 0.01) (Fig. 2b). Overall, we de-
tected subtle changes only in levels of Aβ species in the
CSF of escitalopram-treated mice compared with
vehicle-treated mice.
IHC using the 6E10 antibody showed that plaques of
human Aβ were abundant in the neocortex and the
hippocampus of both escitalopram-treated and
vehicle-treated APP/PS1 mice (Fig. 3a–f ). In the neo-
cortex, we observed that levels of Aβ40 in the
guanidine fraction increased in escitalopram-treated
mice compared with vehicle-treated mice (escitalo-
pram 404 ± 38 pg/mg, vehicle 262 ± 43 pg/mg, p < 0.05)
(Fig. 3g). In the PBS fraction, no differences between
escitalopram-treated and vehicle-treated mice were ob-
served (Fig. 3i). Levels of Aβ42 in the cortical guan-
idine fraction showed a tendency toward an increase in
APP/PS1 mice treated with escitalopram compared with
vehicle-treated mice (escitalopram 2768 ± 212 pg/mg, ve-
hicle 2119 ± 366 pg/mg, p = 0.089) (Fig. 3g), whereas in
the PBS fraction, no differences were observed (Fig. 3i).
We did not detect any differences in the ratios of Aβ42/
Aβ40 in the neocortex (data not shown). None of the Aβ
species were detected in the neocortex of wild-type mice
(Additional file 2: Figure S2). To support the capacity of
the Meso Scale Discovery analysis to detect differences in
Aβ levels, we also quantified total Aβ (Aβ38, Aβ40 and
Aβ42) levels in the neocortex of 6-month-old APP/PS1
mice and compared the level with that of 9-month-old
APP/PS1 mice (Additional file 2: Figure S2). There was a
significantly higher level of total Aβ in both the guanidine
(p < 0.01) and PBS (p < 0.001) fractions in 9-month-old
compared with 6-month-old APP/PS1 mice
(Additional file 2: Figure S2). This is in line with results of
a former study done at our laboratory showing a progres-
sive Aβ accumulation with age in the neocortex of APP/
PS1 mice [22].
Levels of Aβ40 in the guanidine (Fig. 3h) and PBS
(Fig. 3j) fractions of the hippocampus were comparable
in escitalopram-treated and vehicle-treated mice. The
levels of Aβ42 in the guanidine fraction showed a
tendency towards a reduction in mice treated with esci-
talopram compared with vehicle (escitalopram 55.2 ± 2.7
pg/mg, vehicle 72.8 ± 12 pg/mg, p = 0.11) (Fig. 3h).
To further investigate effects of escitalopram treat-
ment on the processing of APP, we quantified levels of
sAPPα and sAPPβ, which are the first cleavage products
of APP during amyloidogenesis. We observed no differ-
ences between vehicle- and escitalopram-treated APP/
PS1 mice in levels of sAPPα in the neocortex (vehicle
0.049 ± 0.009 pg/mg, SSRI 0.056 ± 0.008 pg/mg) (Fig. 4a)
Fig. 1 Escitalopram treatment of APPSWE/PS1ΔE9 (APP/PS1) mice. a, b Autoradiograms showing the binding of the 3-amino-4-(2-dimethylamino-
methylphenylsulfanyl)-benzonitrile radioligand to brain sections from APP/PS1 mice treated with escitalopram (3.83 ± 0.2 mg/kg/day) or vehicle
for 1 month, with non-specific binding (NSB) shown to the right (a). Graphic presentation showing the serotonin transporter occupancy (as a percentage)
in neocortex and hippocampus (b). c–e Escitalopram intake (c), body weight (d) and water intake (e) in the experimental mice treated with escitalopram
from 3 to 9 months of age. The concentration of escitalopram in the drinking water was adjusted to reach 5 mg/kg/day (4.79 ± 0.27 mg/kg/day). Each
coloured line represents one mouse, and the dashed line is the average for all the mice
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or hippocampus (vehicle 0.029 ± 0.004 pg/mg, SSRI
0.030 ± 0.006 pg/mg) (Fig. 4b). In addition, levels of
sAPPβ in the neocortex (Fig. 4c) and hippocampus
(Fig. 4d) were roughly eight-fold higher than levels of
sAPPα and did not differ between groups.
DHT-induced 5-HTergic deafferentation does not influence
amyloid-β levels
Next, we examined if 5-HTergic deafferentation might
affect Aβ levels in the brain. Three-month-old APP/
PS1 mice were given intracerebroventricular injections
of DHT, which induces degeneration of 5-HTergic
neurons in the raphe nuclei [27]. DHT-lesioned and
sham-operated APP/PS1 mice were allowed to survive
until 9 months of age. DHT-lesioned mice appeared
unaffected and showed the same body weight as sham-
operated mice.
To evaluate the efficiency of the 5-HTergic deafferen-
tation, tissue samples of neocortex were analysed for the
content of 5-HT and its metabolite 5-HIAA (Fig. 5).
Levels of 5-HT were reduced by 64% in DHT-lesioned
mice (96.73 ± 10.30 pg/ml) compared with sham-
operated mice (271.00 ± 28.30 pg/ml) (p < 0.0001) (Fig. 5),
whereas 5-HIAA decreased by 62% in DHT-lesioned
mice (52.40 ± 4.50 pg/ml) compared with sham-operated
animals (137.00 ± 15.00 pg/ml) (p < 0.0001) (Fig. 5).
Aβ-containing plaques manifested in the neocortex
and hippocampus of both sham-operated and DHT-
lesioned mice (Fig. 6a–f ). Levels of Aβ40 and Aβ42 in
the guanidine and PBS fractions of the neocortex and
hippocampus were quantified by multiplex analysis
(Fig. 6g–j). We detected no differences in the levels of
Aβ40 and Aβ42 in the guanidine and PBS fractions of
the neocortex in DHT-lesioned mice compared with
sham-operated mice (Fig. 6g, i). Similarly, no differences
in the levels of Aβ40 and Aβ42 in the guanidine and
PBS fractions of the hippocampus were observed in
DHT-lesioned mice compared with sham-operated mice
(Fig. 6h, j). No difference in the Aβ42/Aβ40 ratio was
detected between DHT-lesioned and sham-operated
mice (data not shown).
Similarly to the previous study employing escitalopram,
we also asked whether APP processing would be affected
by 5-HTergic deafferentation of the cortex, so we mea-
sured levels sAPPα and sAPPβ in the neocortex and
hippocampus of sham-operated and DHT-lesioned APP/
PS1 mice (Fig. 7). We noticed that levels of sAPPα in the
neocortex of DHT-lesioned mice decreased significantly
compared with sham-operated APP/PS1 mice (p < 0.05)
(Fig. 7a), whereas no changes were detected in the hippo-
campus (Fig. 7b). Levels of sAPPβ in the neocortex and
hippocampus of sham-operated and DHT-lesioned APP/
PS1 mice did not differ between groups (Fig. 7c, d).
Discussion
Recently, it was reported that SSRI treatment attenu-
ates plaque pathology in the APP/PS1 mouse model of
familial AD [24, 32, 33]. To further test this hypoth-
esis, we treated 3-month-old APP/PS1 mice with the
more selective SSRI escitalopram [34] for a period of 6
months at a dosage of 5 mg/kg/day. This dosage was
predicted to inhibit SERT in the therapeutic range, as
confirmed by a SERT occupancy assay. We did not ob-
serve any changes in body weight, although this is a
common side effect of SSRI treatment in both humans
and rodents [35–37].
Levels of Aβ40 and Aβ42 were analysed in the CSF,
neocortex and hippocampus. In the CSF of APP/PS1
mice, we observed no differences in the levels of Aβ40
and Aβ42 between escitalopram-treated and vehicle-
treated APP/PS1 mice. Studies where human CSF has
been analysed after orally administered SSRIs are am-
biguous and show that although citalopram (2 × 30 mg)
reduces the level of total Aβ in the CSF [32], escitalo-
pram (2 × 20 mg) has no effect on levels of Aβ [38].
Analysis of the CSF of 3-month-old APP/PS1 mice that
Fig. 2 Amyloid-β (Aβ) content in the cerebrospinal fluid (CSF) of
APPSWE/PS1ΔE9 (APP/PS1) mice chronically treated with escitalopram.
a Content of Aβ40 and Aβ42 and (b) the Aβ42/Aβ42 ratio in CSF of
APP/PS1 mice treated with 5 mg/kg/day escitalopram from 3 to 9
months of age. Data are presented as mean ± SEM
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Fig. 3 Amyloid-β (Aβ) content in the brain of APPSWE/PS1ΔE9 (APP/PS1) mice chronically treated with escitalopram. a–f Aβ plaques formed in the
neocortex (a–d) and hippocampus (e and f) of both vehicle-treated (a, c, e) and escitalopram-treated (b, d, f) APP/PS1 mice, shown by 6E10 IHC. Cortical
layers are indicated by roman numerals. DG Dentate gyrus, g Granule cell layer, h Hilus, molecular layer. Scale bars = 50 μm (a, b, e, f), 100 μm (c, d). g
and h Levels of insoluble (guanidine fraction) and soluble (PBS fraction) Aβ40 and Aβ42 in the neocortex (g, i) and hippocampus (h, j) of APP/PS1 after
escitalopram treatment were measured by Meso Scale Discovery multiplex analysis. Data are presented as mean ± SEM and were analysed by unpaired,
two-tailed Mann-Whitney U test. *p< 0.05
Fig. 4 Unchanged levels of soluble amyloid precursor protein α (sAPPα) and sAPPβ in the brain of APPSWE/PS1ΔE9 (APP/PS1) mice chronically
treated with escitalopram. Levels of sAPPα and sAPPβ in the neocortex (a, c) and hippocampus (b, d) of APP/PS1 mice after escitalopram
treatment were measured by Meso Scale Discovery multiplex analysis. Data are presented as mean ± SEM
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were treated for 4 months with orally administered
citalopram (8 mg/kg/day) supports citalopram’s Aβ-
reducing potential [24]. Results additionally suggested
that citalopram’s Aβ-reducing effect was likely due to
reduced production rather than increased clearance of
Aβ [24, 32]. The reason for the absence of an SSRI effect
in our study is unknown. It is possible that the effect on
CSF levels of Aβ of this drug class depends on the type
of SSRI used because escitalopram and citalopram,
though very similar, show different effects in healthy hu-
man subjects. However, as a refinement of the study by
Emilsson et al. [38], it was demonstrated that a single
i.p. injection of 5 mg/kg escitalopram in 3- to 4-month-
old APP/PS1 mice reduced interstitial levels of Aβ in the
hippocampus [39]. Because the interstitial fluid under
normal conditions is in equilibrium with the CSF, this
observation at least shows that escitalopram can have ef-
fects, but it also suggests that some routes of administra-
tion may be more suitable than others.
In the neocortex of APP/PS1 mice treated with escita-
lopram, we observed a tendency toward an increase in
the total content of insoluble Aβ compared with vehicle-
treated mice, which is probably due to an increase in
levels of Aβ40 and, to a lesser extent, Aβ42. We ob-
served no changes in the levels of Aβ40 or Aβ42 in the
hippocampus of escitalopram-treated compared with
vehicle-treated mice. Our observations differ from recent
clinical and in vivo studies in which researchers have re-
ported Aβ-reducing effects of chronic and acute anti-
depressant treatment [24, 25, 32, 33, 40], although
others have also been unable to detect such Aβ-reducing
effects [38, 41]. Human subjects with a history of anti-
depressant drug treatment showed reduced cortical
amyloid load compared with non-treated subjects,
Fig. 5 Serotonin (5-HT) deafferentation in APPSWE/PS1ΔE9 (APP/PS1)
mice with 5,7-dihydroxytryptamine (DHT)-induced lesions. Three-
month-old APP/PS1 mice were lesioned with DHT and, together
with sham-operated mice, allowed to survive until the age of 9
months. Neocortex samples were analysed with high-performance
liquid chromatography, and data showed a 60–65% reduction of
5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA). Data
are presented as mean ± SEM and were analysed by unpaired,
two-tailed Mann-Whitney U test. ****p < 0.0001
Fig. 6 Amyloid-β (Aβ) content in the brain of 5,7-dihydroxytryptamine (DHT)-lesioned APPSWE/PS1ΔE9 (APP/PS1) mice. a–f Aβ plaques formed in the
neocortex (a–d) and hippocampus (e, f) of sham-operated (a, c, e) and DHT-lesioned (b, d, f) APP/PS1 mice, as shown by shown by 6E10 IHC. Cortical
layers are indicated by roman numerals. DG Dentate gyrus, g Granule cell layer, h Hilus, molecular layer. Scale bars = 50 μm (a, b, e, f), 100 μm (c, d).
g–j Levels of insoluble (guanidine fraction) and soluble (PBS fraction) Aβ40 and Aβ42 in the neocortex (g, i) and hippocampus (h, j) of APP/PS1 after
sham operation and DHT-induced lesioning were estimated by Meso Scale Discovery multiplex analysis. Data are presented as mean ± SEM
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estimated by positron emission computed tomographic
imaging using the amyloid-binding [11C]-Pittsburgh
compound B (PIB) radioligand [24]. However, as the au-
thors of that paper pointed out, a randomised clinical
trial is needed to ascertain whether the observed reduc-
tion in PIB binding is indeed caused by SSRI treatment
and not by past history of depression or anxiety. It has
also been shown that 5 months of treatment with parox-
etine i.p. (5 mg/kg/day) reduces Aβ40 levels in the
hippocampus of 10-month-old 3 × Tg mice [25], as
well as that 4 months of treatment with citalopram
(8 mg/kg/day) per os reduces levels of Aβ and plaque
load in the neocortex and hippocampus of 7-month-
old APP/PS1 mice [24]. Treatment with citalopram
(10 mg/kg/day) i.p. for 28 days has furthermore been
shown to completely inhibit the growth of plaques
without affecting their elimination [32]. Results at
our own laboratory have suggested, however, that 9-
month treatment with paroxetine (30 mg/kg/day
being reduced to 10 mg/kg/day and ultimately 5 mg/
kg/day) per os has no effect on plaque load in the
neocortex of 18-month-old APP/PS1 mice [41],
although a significant effect was observed in the
hippocampus of the same mice [40]. Although these
findings suggest that a high dosage of paroxetine
may have an effect on plaque load at least in the
hippocampus, they at the same time emphasise that
paroxetine treatment by no means ameliorates plaque
load when administered to aging mice in which the
amyloid plaques are well-developed.
Escitalopram consists largely of an S-enantiomer,
whereas citalopram used in the other studies is a racemic
mixture of both S- and R-enantiomers in the ratio of 1:1.
Several lines of evidence suggest that the R-enantiomer
may counteract the effect of the S-enantiomer [42], leaving
escitalopram more potent than citalopram. In our opinion,
it is reasonable to assume that a dose of around 5 mg/kg/
day of escitalopram would at least be equivalent to the ef-
fect of 8–10 mg/kg/day of citalopram, which is around the
dose reported to effect amyloidosis in 7-month-old APP/
PS1 mice [24, 32]. It should be noted, however, that She-
line et al. performed an experiment showing that a single
i.p. injection of escitalopram (5 mg/kg/day) reduced the
levels Aβ40 in the hippocampal interstitial fluid of APP/
PS1 mice [39]. Therefore, it is not possible to completely
rule out that escitalopram influences Aβ levels; however,
its effect may depend on whether administration is acute
or chronic, as well as on the route of administration. It is
possible that the R-enantiomer present in citalopram
may elicit Aβ-reducing effects independently of SERT
[38], possibly through a direct influence on APP pro-
cessing [43, 44]. The R-enantiomer has also been found
to exert SERT-independent effects by acting on an orphan
sigma-1 receptor (σ1, Oprs1), affecting axonal outgrowth
and guidance in subpopulations of embryonic thalamocor-
tical neurons [45, 46]. This being said, a single citalopram
Fig. 7 Levels of soluble amyloid precursor protein α (sAPPα) and sAPPβ in the brain of 5,7-dihydroxytryptamine (DHT)-lesioned APPSWE/PS1ΔE9
(APP/PS1) mice. Levels of sAPPα and sAPPβ in the neocortex (a, c) and hippocampus (b, d) of APP/PS1 mice after sham treatment and DHT-
induced lesioning were measured by Meso Scale Discovery multiplex analysis. Data are presented as mean ± SEM and were analysed by unpaired,
two-tailed Mann-Whitney U test. *p < 0.05
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(10 mg/kg) i.p. injection in APP/PS1 mice was reported to
reduce levels of Aβ40 in brain interstitial fluid, possibly
through stimulation of α-secretase activity involved in the
non-amyloidogenic pathway [24]. We therefore also inves-
tigated levels of sAPPα and sAPPβ, which are the first
products of APP processing when cleaved by α- and β-
secretase, respectively. Because we did not detect any dif-
ferences in either sAPPα or sAPPβ protein levels, it is un-
likely that the activities of these enzymes were affected by
the escitalopram treatment in our study.
The APP/PS1 mice that were lesioned with the
neurotoxin DHT were remarkably unaffected by the inter-
vention and showed the same body weight gain as sham-
operated mice, similar to what was reported in a previous
study of shorter duration [27]. Plaques formed in the neo-
cortex and hippocampus of APP/PS1 mice lesioned with
the DHT and in sham-operated mice with similar propen-
sity. Meso Scale Discovery multiplex analysis did not
reveal any significant differences in soluble or insoluble
fractions of Aβ40 or Aβ42 in the neocortex or hippocam-
pus between DHT-lesioned and sham-operated mice. In a
recent study where 7-month-old APP/PS1 mice were
examined 2 weeks after DHT lesioning of the raphe, no
changes in behaviour or Aβ pathology were detected
either. Instead, the authors detected increased tau phos-
phorylation [27], which is not entirely unexpected, how-
ever, because tau phosphorylation increases during
neuronal stress [47, 48]. We also looked into changes in
the levels of sAPPα and sAPPβ to determine whether 5-
HTergic deafferentation would impact the processing of
APP. Interestingly, we found that levels of sAPPα were re-
duced in the neocortex of DHT-lesioned mice. We are not
aware of any studies that have addressed whether α- or β-
secretase is expressed predominantly in fibres or in
somata, however, if α-secretase is mainly expressed in the
5-HTergic terminals, it would be logical to assume that de-
afferentation would reduce its presence. Reduction in the
levels of the α-secretase cleavage product sAPPα were also
independent of production of sAPPβ as well as production
of Aβ. Overall, deafferentation of cortical 5-HT fibres did
not affect levels of Aβ peptides, but it did, however, cause
reduced levels of sAPPα, the biological significance of
which is uncertain.
Conclusions
Our observations do not support chronic escitalopram
treatment as a strategy for anti-Aβ therapy, because we
observed significant increases in the levels of insoluble Aβ
in the neocortex of APP/PS1 mice. 5-HTergic deafferen-
tation of the cortex did not affect the production of Aβ
peptides. However, we did observe a reduction in sAPPα
levels. Overall, our findings do not support modulation of
the 5-HTergic system with the purpose of reducing Aβ
levels in prodromal and early AD.
Additional files
Additional file 1: Figure S1. Pilot study on the escitalopram treatment
experiment. a, b, c In a preliminary escitalopram treatment experiment
(a), concentration was closely monitored for a period of 4 weeks, and
intake was calculated on the basis of body weight (b) and water intake
(c). The average dosage of 3.83 ± 0.2 mg/kg/day is represented by the
dashed line. (PNG 717 kb)
Additional file 2: Figure S2. Validation of the mesoscale analysis.
Levels of total Aβ were measured in the (a) insoluble (guanidine) and (b)
soluble (PBS) fractions in the neocortex of 6-month-old wild-type (n = 2),
and 6- and 9-month-old APP/PS1 mice (n = 12–18). Data are presented as
mean ± SEM and were analysed by unpaired, two-tailed Mann-Whitney U
test. **p < 0.01, ***p < 0.001. (PNG 1888 kb)
Abbreviations
Aβ: Amyloid-β; AD: Alzheimer’s disease; APP: Amyloid precursor protein;
APP/PS1: APPSWE/PS1ΔE9; CSF: Cerebrospinal fluid; [
3H]DASB: 3-Amino-4-
(2-dimethylaminomethylphenylsulfanyl)-benzonitrile; DHT: 5,7-
Dihydroxytryptamine; 5-HIAA: 5-Hydroxyindoleacetic acid;
HPLC: High-performance liquid chromatography; 5-HT: Serotonin;
5-HTergic: Serotonergic; O/N: Overnight; PFA: Paraformaldehyde; PIB: [11C]-
Pittsburgh compound B; RT: Room temperature; sAPP: Soluble amyloid
precursor protein; SB: Sørensen’s Buffer; SERT: Serotonin transporter;
SSRI: Selective serotonin reuptake inhibitor; TBS: Tris-buffered saline;
TBS-T: Tris-buffered saline with 1% Triton X-100; 3 × Tg: Triple transgenic
Acknowledgements
The authors thank Sussanne Petersen for genotyping and mesoscale analysis
and Janne Skalshøj, Mohammad Talal Qasem and Alice Lundsgaard Larsen
for assistance with histology. Rainer Burger is acknowledged for his
assistance with HPLC measurements.
Funding
The study was supported by the Danish Council for Independent Research,
Fonden til Lægevidenskabens Fremme, The Velux Foundation, A. J.
Andersens og Hustrus Fond, Torben og Alice Frimodts Fond and The
Lundbeck Foundation, as well as by SDU2020, a fund created by the
University of Southern Denmark.
Availability of data and materials
Supporting data are presented in Additional file 1: Figure S1 and Additional file
2: Figure S2. All datasets used and/or analysed during the present study are
available from the corresponding author on reasonable request.
Authors’ contributions
CUvL and BF conceived of the study, analysed data and prepared the first
draft of the manuscript. CUvL carried out aspects of the SSRI treatment
study. MG assisted CUvL with surgery and contributed to the preparation of
the manuscript. AM carried out autoradiography. JW carried out HPLC. JW
and KPL contributed along with AM to the preparation of the manuscript.
CUvL, AM, KPL and BF were responsible for the revision of the manuscript.
All authors read and approved the final manuscript.
Ethics approval
Animal experiments were carried out in accordance with the Danish Animal
Inspectorate under the Ministry of Food and Agriculture (2011/562-67 and
2011/561-1950).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
von Linstow et al. Alzheimer's Research & Therapy  (2017) 9:74 Page 10 of 12
Author details
1Department of Neurobiology, Institute of Molecular Medicine, University of
Southern Denmark, J.B. Winsløws Vej 25, 5000 Odense C, Denmark.
2Molecular Psychiatry, Laboratory of Translational Neuroscience, Department
of Psychiatry, Psychosomatics, and Psychotherapy, University of Würzburg,
Fuechsleinstrasse 15, 97080 Würzburg, Germany. 3Laboratory of Psychiatric
Neurobiology, Institute of Molecular Medicine, I.M. Sechenov First Moscow
State Medical University, Moscow, Russia.
Received: 26 May 2017 Accepted: 17 August 2017
References
1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368:
387–403.
2. Bartus RT, Dean 3rd RL, Beer B, Lippa AS. The cholinergic hypothesis of
geriatric memory dysfunction. Science. 1982;217:408–14.
3. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC.
Mental and behavioral disturbances in dementia: findings from the Cache
County Study on Memory in Aging. Am J Psychiatry. 2000;157:708–14.
4. Khaliq S, Haider S, Ahmed SP, Perveen T, Haleem DJ. Relationship of brain
tryptophan and serotonin in improving cognitive performance in rats. Pak J
Pharm Sci. 2006;19:11–5.
5. Hendricksen M, Thomas AJ, Ferrier IN, Ince P, O’Brien JT. Neuropathological
study of the dorsal raphe nuclei in late-life depression and Alzheimer’s
disease with and without depression. Am J Psychiatry. 2004;161:1096–102.
6. Halliday GM, McCann HL, Pamphlett R, Brooks WS, Creasey H, McCusker E,
Cotton RG, Broe GA, Harper CG. Brain stem serotonin-synthesizing neurons in
Alzheimer’s disease: a clinicopathological correlation. Acta Neuropathol. 1992;84:
638–50.
7. Burke WJ, Park DH, Chung HD, Marshall GL, Haring JH, Joh TH. Evidence for
decreased transport of tryptophan hydroxylase in Alzheimer’s disease. Brain
Res. 1990;537:83–7.
8. Francis PT, Palmer AM, Sims NR, Bowen DM, Davison AN, Esiri MM, Neary D,
Snowden JS, Wilcock GK. Neurochemical studies of early-onset Alzheimer’s
disease: possible influence on treatment. N Engl J Med. 1985;313:7–11.
9. Palmer AM, Wilcock GK, Esiri MM, Francis PT, Bowen DM. Monoaminergic
innervation of the frontal and temporal lobes in Alzheimer’s disease. Brain
Res. 1987;401:231–8.
10. Simic G, Stanic G, Mladinov M, Jovanov-Milosevic N, Kostovic I, Hof PR. Does
Alzheimer’s disease begin in the brainstem? Neuropathol Appl Neurobiol.
2009;35:532–54.
11. Von Linstow CU, Severino M, Metaxas A, Waider J, Babcock AA, Lesch KP,
Gramsbergen JB, Finsen B. Effect of aging and Alzheimer’s disease-like
pathology on brain monoamines in mice. Neurochem Int. 2017;108:238–45.
12. Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J,
Kristensen M, Refsum HE, Ofsti E, Eriksson S, Syversen S. A controlled
multicenter clinical study of citalopram and placebo in elderly depressed
patients with and without concomitant dementia. Acta Psychiatr Scand.
1992;86:138–45.
13. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-
controlled study of fluoxetine in depressed patients with Alzheimer’s
disease. Int Psychogeriatr. 2001;13:233–40.
14. Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, Baker
AS, Sheppard JM, Frangakis C, Brandt J, Rabins PV. Treating depression in
Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits
of depression reduction: the DIADS. Arch Gen Psychiatry. 2003;60:737–46.
15. Mowla A, Mosavinasab M, Haghshenas H, Borhani HA. Does serotonin
augmentation have any effect on cognition and activities of daily living in
Alzheimer’s dementia? A double-blind, placebo-controlled clinical trial. J Clin
Psychopharmacol. 2007;27:484–7.
16. Jones HE, Joshi A, Shenkin S, Mead GE. The effect of treatment with
selective serotonin reuptake inhibitors in comparison to placebo in the
progression of dementia: a systematic review and meta-analysis. Age
Ageing. 2016;45:448–56.
17. Kessing LV, Sondergard L, Forman JL, Andersen PK. Antidepressants and
dementia. J Affect Disord. 2009;117:24–9.
18. Mossello E, Boncinelli M, Caleri V, Cavallini MC, Palermo E, Di Bari M, Tilli S,
Sarcone E, Simoni D, Biagini CA, et al. Is antidepressant treatment associated
with reduced cognitive decline in Alzheimer’s disease? Dement Geriatr
Cogn Disord. 2008;25:372–9.
19. Porter RJ, Lunn BS, Walker LL, Gray JM, Ballard CG, O’Brien JT. Cognitive
deficit induced by acute tryptophan depletion in patients with Alzheimer’s
disease. Am J Psychiatry. 2000;157:638–40.
20. Jack Jr CR, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P,
Pankratz VS, Senjem ML, Gunter JL, Mielke MM, et al. Brain β-amyloid load
approaches a plateau. Neurology. 2013;80:890–6.
21. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA,
Copeland NG, Lee MK, Younkin LH, Wagner SL, et al. Mutant presenilins specifically
elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for
augmentation of a 42-specific γ secretase. Hum Mol Genet. 2004;13:159–70.
22. Babcock AA, Ilkjaer L, Clausen BH, Villadsen B, Dissing-Olesen L, Bendixen AT,
Lyck L, Lambertsen KL, Finsen B. Cytokine-producing microglia have an altered
β-amyloid load in aged APP/PS1 Tg mice. Brain Behav Immun. 2015;48:86–101.
23. Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, Mamounas L,
Lyons WE, Blue ME, Lee MK. Amyloid pathology is associated with
progressive monoaminergic neurodegeneration in a transgenic mouse
model of Alzheimer’s disease. J Neurosci. 2008;28:13805–14.
24. Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A,
Hayreh D, D’Angelo G, Benzinger T, Yoon H, et al. Serotonin signaling is
associated with lower amyloid-β levels and plaques in transgenic mice and
humans. Proc Natl Acad Sci U S A. 2011;108:14968–73.
25. Nelson RL, Guo Z, Halagappa VM, Pearson M, Gray AJ, Matsuoka Y, Brown M,
Martin B, Iyun T, Maudsley S, et al. Prophylactic treatment with paroxetine
ameliorates behavioral deficits and retards the development of amyloid and
tau pathologies in 3 × TgAD mice. Exp Neurol. 2007;205:166–76.
26. Noristani HN, Verkhratsky A, Rodriguez JJ. High tryptophan diet reduces CA1
intraneuronal β-amyloid in the triple transgenic mouse model of
Alzheimer’s disease. Aging Cell. 2012;11:810–22.
27. Ramos-Rodriguez JJ, Molina-Gil S, Rey-Brea R, Berrocoso E, Garcia-Alloza M.
Specific serotonergic denervation affects tau pathology and cognition
without altering senile plaques deposition in APP/PS1 mice. PLoS One.
2013;8:e79947.
28. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S.
Occupancy of serotonin transporters by paroxetine and citalopram during
treatment of depression: a [11C]DASB PET imaging study. Am J Psychiatry.
2001;158:1843–9.
29. DeMattos RB, Bales KR, Parsadanian M, O’Dell MA, Foss EM, Paul SM,
Holtzman DM. Plaque-associated disruption of CSF and plasma amyloid-β
(Aβ) equilibrium in a mouse model of Alzheimer’s disease. J Neurochem.
2002;81:229–36.
30. Gutknecht L, Araragi N, Merker S, Waider J, Sommerlandt FM, Mlinar B,
Baccini G, Mayer U, Proft F, Hamon M, et al. Impacts of brain serotonin
deficiency following Tph2 inactivation on development and raphe neuron
serotonergic specification. PLoS One. 2012;7:e43157.
31. Klein N, Sacher J, Geiss-Granadia T, Mossaheb N, Attarbaschi T,
Lanzenberger R, Spindelegger C, Holik A, Asenbaum S, Dudczak R, et al.
Higher serotonin transporter occupancy after multiple dose administration
of escitalopram compared to citalopram: an [123I]ADAM SPECT study.
Psychopharmacology (Berl). 2007;191:333–9.
32. Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, Ficker WD,
Yan P, Xiong CJ, Frederiksen C, et al. An antidepressant decreases CSF Aβ
production in healthy individuals and in transgenic AD mice. Sci Transl
Med. 2014;6:236re4.
33. Fisher JR, Wallace CE, Tripoli DL, Sheline YI, Cirrito JR. Redundant Gs-coupled
serotonin receptors regulate amyloid-β metabolism in vivo. Mol
Neurodegener. 2016;11:45.
34. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human
monoamine transporter binding profile of escitalopram and R-fluoxetine.
Biol Psychiatry. 2001;50:345–50.
35. Mastronardi C, Paz-Filho GJ, Valdez E, Maestre-Mesa J, Licinio J, Wong ML.
Long-term body weight outcomes of antidepressant-environment
interactions. Mol Psychiatry. 2011;16:265–72.
36. Raeder MB, Bjelland I, Emil Vollset S, Steen VM. Obesity, dyslipidemia, and
diabetes with selective serotonin reuptake inhibitors: the Hordaland Health
Study. J Clin Psychiatry. 2006;67:1974–82.
37. Uguz F, Sahingoz M, Gungor B, Aksoy F, Askin R. Weight gain and
associated factors in patients using newer antidepressant drugs. Gen Hosp
Psychiatry. 2015;37:46–8.
38. Emilsson JF, Andreasson U, Blennow K, Eriksson E, Zetterberg H. Comment
on “An antidepressant decreases CSF Aβ production in healthy individuals
and in transgenic AD mice”. Sci Transl Med. 2014;6:268le265.
von Linstow et al. Alzheimer's Research & Therapy  (2017) 9:74 Page 11 of 12
39. Sheline YI, West T, Yarasheski K, Jasielec MS, Hettinger JC, Tripoli DL, Xiong
C, Frederiksen C, Grzelak MV, Bateman RJ, et al. Reply to comment on “An
antidepressant decreases CSF Aβ production in healthy individuals and in
transgenic AD mice”. Sci Transl Med. 2014;6:268lr264.
40. Olesen LØ, Sivasaravanaparan M, Severino M, Babcock AA, Bouzinova EV, West
MJ, Wiborg O, Finsen B. Neuron and neuroblast numbers and cytogenesis in
the dentate gyrus of aged APPswe/PS1dE9 transgenic mice: effect of long-term
treatment with paroxetine. Neurobiol Dis. 2017;104:50–60.
41. Olesen LØ, Bouzinova EV, Severino M, Sivasaravanaparan M, Hasselstrom JB,
Finsen B, Wiborg O. Behavioural phenotyping of APPswe/PS1δE9 mice: age-
related changes and effect of long-term paroxetine treatment. PLoS One.
2016;11:e0165144.
42. Mørk A, Kreilgaard M, Sánchez C. The R-enantiomer of citalopram
counteracts escitalopram-induced increase in extracellular 5-HT in the
frontal cortex of freely moving rats. Neuropharmacology. 2003;45:167–73.
43. Payton S, Cahill CM, Randall JD, Gullans SR, Rogers JT. Drug discovery
targeted to the Alzheimer’s APP mRNA 5′-untranslated region: the action of
paroxetine and dimercaptopropanol. J Mol Neurosci. 2003;20:267–75.
44. Morse LJ, Payton SM, Cuny GD, Rogers JT. FDA-preapproved drugs targeted
to the translational regulation and processing of the amyloid precursor
protein. J Mol Neurosci. 2004;24:129–36.
45. Bonnin A, Zhang L, Blakely RD, Levitt P. The SSRI citalopram affects fetal
thalamic axon responsiveness to netrin-1 in vitro independently of SERT
antagonism. Neuropsychopharmacology. 2012;37:1879–84.
46. Lesch KP, Waider J. Serotonin in the modulation of neural plasticity and
networks: implications for neurodevelopmental disorders. Neuron. 2012;76:
175–91.
47. Ikeda Y, Ishiguro K, Fujita SC. Ether stress-induced Alzheimer-like tau
phosphorylation in the normal mouse brain. FEBS Lett. 2007;581:891–7.
48. Nikkel AL, Martino B, Markosyan S, Brederson JD, Medeiros R, Moeller A,
Bitner RS. The novel calpain inhibitor A-705253 prevents stress-induced tau
hyperphosphorylation in vitro and in vivo. Neuropharmacology. 2012;63:
606–12.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
von Linstow et al. Alzheimer's Research & Therapy  (2017) 9:74 Page 12 of 12
